Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.57
- Piotroski Score 3.00
- Grade Buy
- Symbol (SPRO)
- Company Spero Therapeutics, Inc.
- Price $1.16
- Changes Percentage (-2.52%)
- Change -$0.03
- Day Low $1.14
- Day High $1.23
- Year High $1.89
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
- Last Earnings 08/07/2015
- Ex-Dividend for 5/16 Dividend 09/16/2015
- Dividend Payable 10/07/2015
- Today N/A
- Next Earnings (Estimated) 03/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.44
- Trailing P/E Ratio 3.19
- Forward P/E Ratio 3.19
- P/E Growth 3.19
- Net Income $22.81 M
Income Statement
Quarterly
Annual
Latest News of SPRO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Sprott Joins Rank Of Stocks With 95-Plus Composite Rating
Learn how to identify signals to scale out of losing stocks, and discover the 3 keys to successful stock investing. Sprott stock shows potential with high EPS rating and institutional buying, despite ...
By Investor's Business Daily | 4 days ago -
Investing in Sprott (TSE:SII) five years ago would have delivered you a 141% gain
Despite a recent 10% drop in Sprott Inc.'s share price, its long-term performance has been strong with a 111% return over five years. Analysts suggest focusing on long-term returns rather than short-t...
By Yahoo! Finance | 5 days ago -
Beat the Market Like Zacks: Sprouts Farmers Market, Kroger, Masimo in Focus
The Zacks Model Portfolio of Zacks Rank #1 stocks has outperformed the S&P index by 13% since 1988. Zacks Recommendations, Focus List, ECAP, ECDP, and Top 10 stocks have also shown impressive returns....
By Yahoo! Finance | 1 week ago
